



Application No.: 10/658,219

Docket No.: 559662000102

REMARKS

The claims have been amended to limit them to "native" Factor VIII.

It is understood from previous prosecution that "native" Factor VIII is understood to mean Factor VIII that has not been treated with an activating agent such as thrombin so as to form an "activated" form. This was addressed in the prosecution of the copending continuation of the parent application, said continuation having U.S. Serial No. 09/888,734 filed 25 June 2001. Support for the additional language in claim 9 is found in the specification on page 2 in the paragraph immediately preceding Example 1. Support for the additional language in claim 11 is found at the bottom of page 1 of the specification. No new matter has been added and prosecution on the merits is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. **559662000102**.

Respectfully submitted,

Dated: August 25, 2004

By: Kate H. Murashige
Kate H. Murashige
Registration No. 29,959

Morrison & Foerster LLP
3811 Valley Centre Drive,
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125